Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...
Silexion Therapeutics (SLXN) Gets a Buy from Maxim Group
In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with ...
Why Is Silexion Therapeutics Stock Soaring Over 100% On Tuesday?
Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...
Silexion Therapeutics reports preclinical data for SIL-204
Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...
Pre-market Movers: China Liberal Education, CARGO Therapeutics, Tectonic Therapeutic, Silexion Therapeutics, Banzai International
The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green Tectonic Therapeutic, Inc. (TECX) is up over ...
Silexion reports breakthrough in KRAS cancer therapy
CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...
Le Lézard1d
Trapped in CPAP Dependency? Vivos Liberates OSA Patients with Non-Invasive Solution
CPAP therapy, the traditional standard for obstructive sleep apnea (OSA), is universally despised by patients, resulting in abysmally low compliance rates. Recent studies show it also fails to ...
Seeking Alpha3d
SLXNW Silexion Therapeutics Corp Wt Exp
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...
manilatimes15d
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) ("Silexion Therapeutics” or the "Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS ...
Nasdaq17d
Silexion Therapeutics to Present at 2025 ASCO Gastrointestinal Cancers Symposium on Innovative RNAi Therapy for KRAS-Driven Cancers
Silexion Therapeutics Corp. announced that it will present a poster at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco, scheduled for January 23-25, 2025. The presentation will ...
Morningstar15d
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi ...